MENU

DTIL Stock Precision BioSciences (DTIL, $8.94) Aroon Indicator entered a Downtrend on October 18, 2024.

A.I.dvisor
at Tickeron.com
10/19/24
Loading...
DTIL - Precision BioSciences
Aroon signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Aroon signal
Price: $8.94
Daily change: -$0.02 (-0.22%)
Daily volume: 42.9K
Industry: Biotechnology
For the last three days, A.I.dvisor has detected that DTIL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for DTIL, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 318 similar cases, of which were successful. Based on this data, the odds of success are

DTIL's Indicator enters downward trend

The Aroon Indicator for DTIL entered a downward trend on October 18, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 318 similar instances where the Aroon Indicator formed such a pattern. In of the 318 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 04, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on DTIL as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DTIL turned negative on September 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

DTIL moved below its 50-day moving average on September 18, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DTIL crossed bearishly below the 50-day moving average on September 27, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTIL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DTIL advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.868) is normal, around the industry mean (12.594). P/E Ratio (34.108) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). DTIL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.511) is also within normal values, averaging (224.025).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DTIL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DTIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
DTIL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of technology to produce custom, genome-editing enzymes for human health and biological research

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
302 East Pettigrew Street
Phone
+1 919 314-5512
Employees
109
Web
https://www.precisionbiosciences.com